^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation For The Treatment Of Sortilin-Expressing Cancers

Published date:
02/04/2021
Excerpt:
Theratechnologies Inc....is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.
Trial ID: